.Attribute Medication, Posted online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) therapy of people with HER2+ innovative breast cancer cells and also active or steady human brain metastases showed steady intracranial activity as well as systemic effectiveness of T-DXd.